{"pmid":32365233,"title":"Guidelines for the management of diabetes services and patients during the COVID-19 pandemic.","text":["Guidelines for the management of diabetes services and patients during the COVID-19 pandemic.","The UK National Diabetes Inpatient COVID Response Group was formed at the end of March 2020 to support the provision of diabetes inpatient care during the COVID pandemic. It was formed in response to two emerging needs. First to ensure that basic diabetes services are secured and maintained at a time when there was a call for re-deployment to support the need for general medical expertise across secondary care services. The second was to provide simple safe diabetes guidelines for use by specialists and non-specialists treating inpatients with or suspected of COVID-19 infection. To date the group, comprising UK-based specialists in diabetes, pharmacy and psychology, have produced two sets of guidelines which will be continually revised as new evidence emerges. It is supported by Diabetes UK, the Association of British Clinical Diabetologists and NHS England.","Diabet Med","Rayman, G","Lumb, A","Kennon, B","Cottrell, C","Nagi, D","Page, E","Voigt, D","Courtney, H","Atkins, H","Platts, J","Higgins, K","Dhatariya, K","Patel, M","Narendran, P","Kar, P","Newland-Jones, P","Stewart, R","Burr, O","Thomas, S","32365233"],"abstract":["The UK National Diabetes Inpatient COVID Response Group was formed at the end of March 2020 to support the provision of diabetes inpatient care during the COVID pandemic. It was formed in response to two emerging needs. First to ensure that basic diabetes services are secured and maintained at a time when there was a call for re-deployment to support the need for general medical expertise across secondary care services. The second was to provide simple safe diabetes guidelines for use by specialists and non-specialists treating inpatients with or suspected of COVID-19 infection. To date the group, comprising UK-based specialists in diabetes, pharmacy and psychology, have produced two sets of guidelines which will be continually revised as new evidence emerges. It is supported by Diabetes UK, the Association of British Clinical Diabetologists and NHS England."],"journal":"Diabet Med","authors":["Rayman, G","Lumb, A","Kennon, B","Cottrell, C","Nagi, D","Page, E","Voigt, D","Courtney, H","Atkins, H","Platts, J","Higgins, K","Dhatariya, K","Patel, M","Narendran, P","Kar, P","Newland-Jones, P","Stewart, R","Burr, O","Thomas, S"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32365233","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dme.14316","locations":["GBR","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138496062980097,"score":9.490897,"similar":[{"pmid":32369634,"title":"Guidelines for the management of diabetes in care homes during the Covid-19 pandemic.","text":["Guidelines for the management of diabetes in care homes during the Covid-19 pandemic.","The National Diabetes Stakeholders Covid-19 Response Group was formed in early April 2020 as a rapid action by the Joint British Diabetes Societies for Inpatient Care, Diabetes UK, the Association of British Clinical Diabetologists, and Diabetes Frail to address and support the special needs of residents with diabetes in UK care homes during Covid-19. It was becoming obvious that the care home sector was becoming a second wave of Covid-19 infection and that those with diabetes residing in care homes were at increased risk not only of susceptibility to infection but also to poorer outcomes. Its key purposes included minimising the morbidity and mortality associated with Covid-19 and assisting care staff to identify those residents with diabetes at highest risk of Covid-19 infection. The guidance was particularly created for care home managers, other care home staff, and specialist and non-specialist community nursing teams. The guidance covers the management of hyperglycaemia by discussion of various clinical scenarios that could arise, the management of hypoglycaemia, foot care and end of life care. In addition, it outlines the conditions where hospital admission is required. The guidance should be regarded as interim and will be updated as further medical and scientific evidence becomes available.","Diabet Med","Sinclair, Alan","Dhatariya, Ketan","Burr, Olivia","Nagi, Dinesh","Higgins, Kath","Hopkins, David","Patel, Mayank","Kar, Partha","Gooday, Catherine","Howarth, Dan","Abdelhafiz, Ahmed","Newland-Jones, Philip","O'Neill, Simon","32369634"],"abstract":["The National Diabetes Stakeholders Covid-19 Response Group was formed in early April 2020 as a rapid action by the Joint British Diabetes Societies for Inpatient Care, Diabetes UK, the Association of British Clinical Diabetologists, and Diabetes Frail to address and support the special needs of residents with diabetes in UK care homes during Covid-19. It was becoming obvious that the care home sector was becoming a second wave of Covid-19 infection and that those with diabetes residing in care homes were at increased risk not only of susceptibility to infection but also to poorer outcomes. Its key purposes included minimising the morbidity and mortality associated with Covid-19 and assisting care staff to identify those residents with diabetes at highest risk of Covid-19 infection. The guidance was particularly created for care home managers, other care home staff, and specialist and non-specialist community nursing teams. The guidance covers the management of hyperglycaemia by discussion of various clinical scenarios that could arise, the management of hypoglycaemia, foot care and end of life care. In addition, it outlines the conditions where hospital admission is required. The guidance should be regarded as interim and will be updated as further medical and scientific evidence becomes available."],"journal":"Diabet Med","authors":["Sinclair, Alan","Dhatariya, Ketan","Burr, Olivia","Nagi, Dinesh","Higgins, Kath","Hopkins, David","Patel, Mayank","Kar, Partha","Gooday, Catherine","Howarth, Dan","Abdelhafiz, Ahmed","Newland-Jones, Philip","O'Neill, Simon"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369634","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dme.14317","keywords":["covid-19","diabetes","care homes","frailty","insulin","residents"],"locations":["GBR","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138496241238016,"score":479.42535},{"pmid":32418245,"title":"New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic.","text":["New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic.","The COVID-19 pandemic has had a dramatic impact on the provision of acute inpatient care with specialists from all disciplines having to manage patients outside of their usual speciality areas. In many UK hospitals diabetes consultants and diabetes inpatient specialist nurses have been redeployed to the wards to care for COVID-19 positive or suspected cases. Consequently, clinicians relatively unfamiliar with managing hyperglycaemia have been required to do so as the usual input from diabetes specialist teams has not been possible in many areas.","Diabet Med","Rayman, G","Lumb, A","Kennon, B","Cottrell, C","Nagi, D","Page, E","Voigt, D","Courtney, H","Atkins, H","Platts, J","Higgins, K","Dhatariya, K","Patel, M","Narendran, P","Kar, P","Newland-Jones, P","Stewart, R","Burr, O","Thomas, S","32418245"],"abstract":["The COVID-19 pandemic has had a dramatic impact on the provision of acute inpatient care with specialists from all disciplines having to manage patients outside of their usual speciality areas. In many UK hospitals diabetes consultants and diabetes inpatient specialist nurses have been redeployed to the wards to care for COVID-19 positive or suspected cases. Consequently, clinicians relatively unfamiliar with managing hyperglycaemia have been required to do so as the usual input from diabetes specialist teams has not been possible in many areas."],"journal":"Diabet Med","authors":["Rayman, G","Lumb, A","Kennon, B","Cottrell, C","Nagi, D","Page, E","Voigt, D","Courtney, H","Atkins, H","Platts, J","Higgins, K","Dhatariya, K","Patel, M","Narendran, P","Kar, P","Newland-Jones, P","Stewart, R","Burr, O","Thomas, S"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418245","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/dme.14327","locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1667058206805852161,"score":342.48508},{"pmid":32383989,"title":"The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.","text":["The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth.","Background: The Stay at Home order in Colorado and The Stay Safe at Home order in California during COVID-19 pandemic have forced a majority of the endocrinologists/diabetologists to adapt to providing diabetes care remotely through telehealth. This may provide increased access to diabetes health care in certain settings. However, health care disparities continue to challenge availability of diabetes technologies for underprivileged communities. We report our experience with two patients providing diabetes care effectively and preventing hospital admissions by using telehealth. Methods: Two adult patients with type 1 diabetes (T1D): one new onset and the other one with established T1D are presented where telehealth facilitated by Clarity Software and the \"Share\" feature with the use of Dexcom G6 continuous glucose monitoring (CGM) for management of diabetic ketosis and hyperglycemia. Results: Both patients were managed effectively virtually despite higher risk of diabetic ketoacidosis (DKA). Shared glucose data through CGM facilitated frequent insulin dose adjustments, increased fluid and carbohydrate intake, and prevented hospital admissions in both cases. In the case of new onset patient with T1D, most of the education was done remotely by certified diabetes care and education specialists. Conclusion: Acute diabetes complication like DKA increases morbidity and mortality in addition to adding cost to the health care system. The current pandemic of COVID-19 has allowed newer ways (with the help of newer technologies) to manage high-risk patients with T1D and DKA through telehealth and may result in lasting benefits to people with T1D.","Diabetes Technol Ther","Peters, Anne L","Garg, Satish","32383989"],"abstract":["Background: The Stay at Home order in Colorado and The Stay Safe at Home order in California during COVID-19 pandemic have forced a majority of the endocrinologists/diabetologists to adapt to providing diabetes care remotely through telehealth. This may provide increased access to diabetes health care in certain settings. However, health care disparities continue to challenge availability of diabetes technologies for underprivileged communities. We report our experience with two patients providing diabetes care effectively and preventing hospital admissions by using telehealth. Methods: Two adult patients with type 1 diabetes (T1D): one new onset and the other one with established T1D are presented where telehealth facilitated by Clarity Software and the \"Share\" feature with the use of Dexcom G6 continuous glucose monitoring (CGM) for management of diabetic ketosis and hyperglycemia. Results: Both patients were managed effectively virtually despite higher risk of diabetic ketoacidosis (DKA). Shared glucose data through CGM facilitated frequent insulin dose adjustments, increased fluid and carbohydrate intake, and prevented hospital admissions in both cases. In the case of new onset patient with T1D, most of the education was done remotely by certified diabetes care and education specialists. Conclusion: Acute diabetes complication like DKA increases morbidity and mortality in addition to adding cost to the health care system. The current pandemic of COVID-19 has allowed newer ways (with the help of newer technologies) to manage high-risk patients with T1D and DKA through telehealth and may result in lasting benefits to people with T1D."],"journal":"Diabetes Technol Ther","authors":["Peters, Anne L","Garg, Satish"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383989","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1089/dia.2020.0187","keywords":["cgm","covid-19","diabetic ketoacidosis","health care disparities","new onset type 1 diabetes","telehealth"],"locations":["Colorado","California"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Silver","Carbohydrates","Glucose"],"topics":["Prevention"],"weight":1,"_version_":1666419683378593792,"score":240.60083},{"pmid":32396395,"title":"Inpatient Transition to Virtual Care During COVID-19 Pandemic.","text":["Inpatient Transition to Virtual Care During COVID-19 Pandemic.","Introduction: During the coronavirus disease 2019 (COVID-19) outbreak, novel approaches to diabetes care have been employed. Care in both the inpatient and outpatient setting has transformed considerably. Driven by the need to reduce the use of personal protective equipment and exposure for patients and providers alike, we transitioned inpatient diabetes management services to largely \"virtual\" or remotely provided care at our hospital. Methods: Implementation of a diabetes co-management service under the direction of the University of North Carolina division of endocrinology was initiated in July 2019. In response to the COVID-19 pandemic, the diabetes service was largely transitioned to a virtual care model in March 2020. Automatic consults for COVID-19 patients were implemented. Glycemic outcomes from before and after transition to virtual care were evaluated. Results: Data over a 15-week period suggest that using virtual care for diabetes management in the hospital is feasible and can provide similar outcomes to traditional face-to-face care. Conclusion: Automatic consults for COVID-19 patients ensure that patients with serious illness receive specialized diabetes care. Transitioning to virtual care models does not limit the glycemic outcomes of inpatient diabetes care and should be employed to reduce patient and provider exposure in the setting of COVID-19. These findings may have implications for reducing nosocomial infection in less challenging times and might address shortage of health care providers, especially in the remote areas.","Diabetes Technol Ther","Jones, Morgan S","Goley, April L","Alexander, Bonnie E","Keller, Scott B","Caldwell, Marie M","Buse, John B","32396395"],"abstract":["Introduction: During the coronavirus disease 2019 (COVID-19) outbreak, novel approaches to diabetes care have been employed. Care in both the inpatient and outpatient setting has transformed considerably. Driven by the need to reduce the use of personal protective equipment and exposure for patients and providers alike, we transitioned inpatient diabetes management services to largely \"virtual\" or remotely provided care at our hospital. Methods: Implementation of a diabetes co-management service under the direction of the University of North Carolina division of endocrinology was initiated in July 2019. In response to the COVID-19 pandemic, the diabetes service was largely transitioned to a virtual care model in March 2020. Automatic consults for COVID-19 patients were implemented. Glycemic outcomes from before and after transition to virtual care were evaluated. Results: Data over a 15-week period suggest that using virtual care for diabetes management in the hospital is feasible and can provide similar outcomes to traditional face-to-face care. Conclusion: Automatic consults for COVID-19 patients ensure that patients with serious illness receive specialized diabetes care. Transitioning to virtual care models does not limit the glycemic outcomes of inpatient diabetes care and should be employed to reduce patient and provider exposure in the setting of COVID-19. These findings may have implications for reducing nosocomial infection in less challenging times and might address shortage of health care providers, especially in the remote areas."],"journal":"Diabetes Technol Ther","authors":["Jones, Morgan S","Goley, April L","Alexander, Bonnie E","Keller, Scott B","Caldwell, Marie M","Buse, John B"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396395","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1089/dia.2020.0206","keywords":["covid-19","diabetes mellitus","hospital medicine","inpatient medicine","telehealth","telemedicine","virtual care"],"topics":["Prevention"],"weight":1,"_version_":1666627827897729025,"score":231.4324},{"pmid":32333691,"title":"Managing People with Diabetes Fasting for Ramadan During the COVID-19 Pandemic: A South Asian Health Foundation Update.","text":["Managing People with Diabetes Fasting for Ramadan During the COVID-19 Pandemic: A South Asian Health Foundation Update.","The month of Ramadan forms one of the five pillars of the Muslim faith. Adult Muslims are obligated to keep daily fasts from dawn to sunset, with exceptions. This year Ramadan is due to begin on 23 April 2020 and the longest fast in the UK will be approximately 18 hours in length. In addition, due to the often high-calorie meals eaten to break the fast, Ramadan should be seen as a cycle of fasting and feasting. Ramadan fasting can impact those with diabetes, increasing the risk of hypoglycaemia, hyperglycaemia and dehydration. This year, Ramadan will occur during the global COVID-19 pandemic. Reports show that diabetes appears to be a risk factor for more severe disease with COVID-19. In addition, the UK experience has shown diabetes and COVID-19 is associated with dehydration, starvation ketosis, diabetic ketoacidosis and hyperglycaemic hyperosmolar state. This makes fasting in Ramadan particularly challenging for those Muslims with diabetes. Here, we discuss the implications of fasting in Ramadan during the COVID-19 pandemic and make recommendations for those with diabetes who wish to fast.","Diabet Med","Hanif, S","Ali, S N","Hassanein, M","Khunti, K","Hanif, W","32333691"],"abstract":["The month of Ramadan forms one of the five pillars of the Muslim faith. Adult Muslims are obligated to keep daily fasts from dawn to sunset, with exceptions. This year Ramadan is due to begin on 23 April 2020 and the longest fast in the UK will be approximately 18 hours in length. In addition, due to the often high-calorie meals eaten to break the fast, Ramadan should be seen as a cycle of fasting and feasting. Ramadan fasting can impact those with diabetes, increasing the risk of hypoglycaemia, hyperglycaemia and dehydration. This year, Ramadan will occur during the global COVID-19 pandemic. Reports show that diabetes appears to be a risk factor for more severe disease with COVID-19. In addition, the UK experience has shown diabetes and COVID-19 is associated with dehydration, starvation ketosis, diabetic ketoacidosis and hyperglycaemic hyperosmolar state. This makes fasting in Ramadan particularly challenging for those Muslims with diabetes. Here, we discuss the implications of fasting in Ramadan during the COVID-19 pandemic and make recommendations for those with diabetes who wish to fast."],"journal":"Diabet Med","authors":["Hanif, S","Ali, S N","Hassanein, M","Khunti, K","Hanif, W"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333691","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dme.14312","keywords":["covid-19","diabetes","ramadan","pandemic"],"locations":["Muslim","Adult Muslims","GBR","GBR","Muslims"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138494005673984,"score":207.82884}]}